Economic Burden of Bladder Cancer Across the European Union
Economic Burden of Bladder Cancer Across the European Union
复制标题
DOI：
10.1016/j.eururo.2015.10.024
复制
发表时间：
2016-03-01
期刊：
影响因子：
23.4
通讯作者：
Witjes, J. Alfred
中科院分区：
文献类型：
--
作者：
Leal, Jose;Luengo-Fernandez, Ramon;Witjes, J. Alfred
背景：在欧盟28个国家中，每年有超过12万人被诊断患有膀胱癌。每年有40万人死于肺癌，它是癌症的第六大原因。然而，到目前为止，还没有系统的疾病成本研究评估膀胱癌在欧盟的经济影响。目的：估计2012年欧盟膀胱癌的年度经济成本。设计、环境和参与者：使用从众多国际和国家来源获得的发病率、死亡率和卫生保健资源使用的汇总数据来估计特定国家的癌症成本数据。结果测量和统计分析：根据初级、门诊、急诊和住院治疗以及药物的支出估计医疗保健费用。对因发病和过早死亡而造成的无偿护理费用和收入损失进行了估计。结果和局限性：膀胱癌在2012年花费了欧盟（sic） 49亿美元，其中医疗保健占（sic） 29亿美元（59%），占癌症医疗保健总费用的5%。2012年，膀胱癌占欧盟所有癌症费用的3%（（原语）1430亿），每年每10名欧盟公民的医疗费用为（原语）57英镑，费用最低的国家保加利亚（（原语）每10名公民8英镑）和费用最高的国家卢森堡（（原语）93英镑）之间的费用相差10倍。生产力损失和非正式护理分别占膀胱癌费用的23%和18%。在整个欧盟范围内，可比较的癌症相关数据的质量和可用性需要进一步提高。结论：我们的研究结果为提供负担得起的膀胱癌治疗系统和优先分配公共研究资金提供了必要的公共卫生和政策情报。患者总结：我们研究了整个欧盟（EU）膀胱癌的经济成本。我们发现膀胱癌在2012年花费了49亿美元，其中医疗保健花费了29亿美元。我们的研究提供的数据可用于告知欧盟负担得起的癌症治疗。(C) 2015年欧洲泌尿外科协会。Elsevier B.V.出版
Background: More than 120 000 people are diagnosed annually with bladder cancer in the 28 countries of the European Union (EU). With > 40 000 people dying of it each year, it is the sixth leading cause of cancer. However, to date, no systematic cost-of-illness study has assessed the economic impact of bladder cancer in the EU.Objective: To estimate the annual economic costs of bladder cancer in the EU for 2012.Design, setting, and participants: Country-specific cancer cost data were estimated using aggregate data on morbidity, mortality, and health care resource use, obtained from numerous international and national sources.Outcome measurements and statistical analysis: Health care costs were estimated from expenditures on primary, outpatient, emergency, and inpatient care, as well as medications. Costs of unpaid care and lost earnings due to morbidity and early death were estimated.Results and limitations: Bladder cancer cost the EU (sic)4.9 billion in 2012, with health care accounting for (sic)2.9 billion (59%) and representing 5% of total health care cancer costs. Bladder cancer accounted for 3% of all cancer costs in the EU ((sic)143 billion) in 2012 and represented an annual health care cost of (sic)57 per 10 EU citizens, with costs varying > 10 times between the country with the lowest cost, Bulgaria ((sic)8 for every 10 citizens), and highest cost, Luxembourg ((sic)93). Productivity losses and informal care represented 23% and 18% of bladder cancer costs, respectively. The quality and availability of comparable cancer-related data across the EU need further improvement.Conclusions: Our results add to essential public health and policy intelligence for delivering affordable bladder cancer care systems and prioritising the allocation of public research funds.Patient summary: We looked at the economic costs of bladder cancer across the European Union (EU). We found bladder cancer to cost (sic)4.9 billion in 2012, with health care accounting for (sic)2.9 billion. Our study provides data that can be used to inform affordable cancer care in the EU. (C) 2015 European Association of Urology. Published by Elsevier B.V.